<DOC>
	<DOCNO>NCT00240500</DOCNO>
	<brief_summary>The purpose study evaluate persistence anti-hepatitis B surface antigen ( anti-HBs ) antibodies 16 , 17 , 18 , 19 20 year administration first dose study vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Follow-up Study 16-20 Years After Primary Vaccination Against Hepatitis B Newborns From HBeAg+ &amp; HBsAg+ Mothers</brief_title>
	<detailed_description>The primary study design evaluate immunogenicity protective efficacy hepatitis B vaccine newborn HBeAg+ HBsAg+ mother comparison historical control group . The present study carry evaluate anti-HBs persistence 16-20 year first vaccine dose investigate prevalence incidence hepatitis B marker clinical significance time point Year 16-20 . No additional subject recruit long-term follow-up study vaccine administer .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects receive least one dose study vaccine primary study ( 103860/064 ) Written informed consent obtain subject blood sample visit</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>20 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Long-term follow-up</keyword>
	<keyword>Hepatitis B antibody persistence</keyword>
</DOC>